Currently, CD19 CAR T-cell have been approved by the FDA for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL) (10). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.